| Similar Articles |
|---|
 |
The Motley Fool
February 15, 2011
Rich Smith |
What's Behind the Run-Up at Exelixis? One word: earnings. Shares of this tiny drug developer have taken off like a rocket.   |
The Motley Fool
March 21, 2011
Brian Orelli |
Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug. |
BusinessWeek
May 16, 2005
Arlene Weintraub |
Bristling With Promise Start-up Curis is developing a class of drugs that could halt hair loss -- and treat cancer |
BusinessWeek
December 13, 2004
Gene G. Marcial |
Rich Suitors May Come Courting Curis With Genentech, Johnson & Johnson, and Wyeth as its partners, tiny Curis is a "sitting duck" for a takeover as it develops drugs to combat a number of diseases. One hedge-fund manager puts Curis' buyout value at $9 a share. |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
The Motley Fool
March 17, 2008
Brian Lawler |
Genentech Takes Center Stage There might be more partnerships in store for this drugmaker. |
The Motley Fool
June 21, 2011
Brian Orelli |
Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen. |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
The Motley Fool
November 30, 2011
Brian Orelli |
In Drug Development, Help Is Crucial Curis announced a partnership with The Leukemia & Lymphoma Society to fund the development of its preclinical compound CUDC-907. |
The Motley Fool
March 29, 2007
Brian Lawler |
Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note. |
The Motley Fool
January 11, 2005
W.D. Crotty |
Genentech's Pricey DNA The company continues to churn out sales and earnings gains, but it looks richly priced. |
The Motley Fool
January 25, 2007
Charly Travers |
The Best Drug Stock for 2007 Is ... Is anyone surprised that the largest biotech company in the world, Genentech, came out on top? |
The Motley Fool
June 21, 2010
Erin Kutz |
Curis Misses Mark in Drug Trial; Genzyme Elects Board; GTC Cuts Jobs; and More Boston-Area Life Sciences News These drug and biomedical companies made news last week. |
